4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
InMed Pharmaceuticals Inc. (INM) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Vancouver, Canada with about 6 employees. Its market capitalization is roughly $9 million. In the fiscal year ended 2026-06-30, INM reported $0M in revenue and ($13M) in net income.
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products.
Interactive charts & full statements → Open the INM valuation workbench →
| Income statement | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $5M | $4M | — |
| Gross Profit | — | $2M | $1M | $1M | $0M |
| Operating Income (EBIT) | ($10M) | ($8M) | ($8M) | ($8M) | — |
| Net Income | ($13M) | ($8M) | ($8M) | ($8M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $1M | $1M | $1M | — |
| Gross Profit | — | — | $0M | $0M | $1M | $0M |
| Operating Income (EBIT) | ($3M) | ($3M) | ($2M) | ($2M) | ($2M) | — |
| Net Income | ($6M) | ($3M) | ($2M) | ($2M) | ($2M) | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Total Assets | $3M | $16M | $12M | $14M | — |
| Total Liabilities | $2M | $2M | $3M | $2M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive INM viewer.
About TickerBase · Data methodology & sources · Privacy · Terms